International Faculty Spotlight
#ISNCON26
A pioneering physician-scientist whose work has transformed our understanding of kidney disease & preeclampsia, Dr. Anant Karumanchi @ananthmsn34 will deliver the prestigious K S Chugh Oration✨
📍 Kochi
📅 Dec 17–20, 2026
Register now⏰
*When Positivity Misleads: Recognizing False Signals in SAB Testing*
***********************
⚡SAB positivity can represent artefact rather than true immunologic risk
⚡High MFI alone is unreliable without pattern and clinical context
⚡A broad, tapering (“long-tail”) pattern suggests non-specific reactivity
⚡Lack of sensitization history should prompt cautious interpretation
⚡FlowPRA and FCXM discordance helps identify non-clinical antibodies
⚡Absence of a shared epitope supports non-specific binding
⚡Misinterpretation can lead to false DSA assignment and inflated cPRA
⚡Result in unnecessary exclusion of compatible donors
⚡Always interpret SAB results in integration with clinical and laboratory correlation
⚡Pattern recognition is more reliable than numerical thresholds
#KKNephBytes#Immunology@arvindcanchi@DrAkshayaJ@drshyambansal@hardik4u24@isn_india@priti899@suhalikapath@AnjanaGopal9@raja_1980@dr_sourabha@iamnephrologist
*HLA-DQ Antibodies: The Silent Cracker That Starts the Blast*
***************************
⚡HLA-DQ antibodies are the most common de novo DSA
⚡HLA-DQ DSA have the worst graft outcomes (ABMR, TG, graft loss)
⚡DQ mismatch carries the highest risk of sensitization (↑cPRA)
⚡ HLA-DQ has dual polymorphism (α β chains)
⚡Can form multiple heterodimers (cis trans pairing)
⚡ More heterodimers → more epitopes → higher immunogenicity
⚡ HLA-DQ shows low expression but high pathogenicity
⚡ Expression is delayed but sustained → chronic rejection
⚡ DQ antibodies activate Akt / S6 / IL-6 pathways
⚡ Current matching underestimates DQ risk
⚡ Eplet/pairing-based analysis > antigen matching
#KKNephBytes#Immunology@arvindcanchi@DrAkshayaJ@drshyambansal@hardik4u24@isn_india@priti899@suhalikapath@JJayameena